Mesenchymal stem cells and uses therefor

• US 10,668,101 B2
• Filed: 12/23/2013
• Issued: 06/02/2020
• Est. Priority Date: 03/22/2004
• Status: Active Grant

• Current Assignee: Mesoblast International Srl
• Original Assignee: Mesoblast International Srl
• Inventors: Aggarwal, Sudeepta, Pittenger, Mark F., Varney, Timothy
• Primary Examiner(s): Long, Scott
• Application Number:
  US14/138,577
• Publication Number:
  US 20140161776A1
• Time in Patent Office: 2,353 Days
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/2026 IL-4
• CPC Class Codes: A61K 38/2066 IL-10
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/14 : of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 5/0662 : Stem cells
• CPC Class Codes: C12N 5/0663 : Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0664 : Dental pulp stem cells, Dental follicle stem cells
• CPC Class Codes: C12N 5/0665 : Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
• CPC Class Codes: C12N 5/0666 : Mesenchymal stem cells from hair follicles
• CPC Class Codes: C12N 5/0667 : Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/0668 : Mesenchymal stem cells from other natural sources
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Claims

1. A method of limiting inflammation in the gut in a patient suffering from inflammatory bowel disease, the method comprising the step of intravenously or intraarterially administering to the patient a suspension of isolated, cultured, genetically unmanipulated mesenchymal stem cells in an amount effective to limit the inflammation in the gut.

2. The method of claim 1, wherein the suspension further comprises an acceptable pharmaceutical carrier.

3. The method of claim 1, wherein the suspension is administered in an amount of from about 1×

10⁵ cells/kg to about 1×

10⁷ cells/kg.

4. The method of claim 1, wherein the suspension is administered in an amount of from about 1×

10⁶ cells/kg to about 5×

10⁶ cells/kg.

5. The method of claim 1, wherein the cultured, genetically unmanipulated mesenchymal stem cells are isolated from marrow.

6. The method of claim 5, wherein the marrow is iliac crest marrow.

7. The method of claim 1, wherein the administration is intravenous.

8. The method of claim 5, wherein the administration is intravenous.

9. The method of claim 6, wherein the administration is intravenous.

10. The method of claim 1, wherein the administration is intraarterial.

11. The method of claim 5, wherein the administration is intraarterial.

12. The method of claim 6, wherein the administration is intraarterial.

13. The method of claim 1, wherein the mesenchymal stem cells increase secretion of interleukin-10.

14. The method of claim 1, wherein the mesenchymal stem cells increase generation of regulatory T cells.

15. The method of claim 1, wherein the patient is human and the mesenchymal stem cells are human.

16. The method of claim 7, wherein the patient is human and the mesenchymal stem cells are human.

17. The method of claim 10, wherein the patient is human and the mesenchymal stem cells are human.